Ku, Elaine;
Del Vecchio, Lucia;
Eckardt, Kai-Uwe;
Haase, Volker H;
Johansen, Kirsten L;
Nangaku, Masaomi;
Tangri, Navdeep;
... for Conference Participants; + view all
(2023)
Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
10.1016/j.kint.2023.05.009.
(In press).
Preview |
Text
Wheeler_KI-03-23-0298 KDIGO Anemia 2 conf report May 9 resubmit KI 09-05-23 (2).pdf Download (794kB) | Preview |
Abstract
Anemia is common in patients with chronic kidney disease (CKD) and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in CKD. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned two Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here we report on the second of these conferences held virtually in December 2021 which focused on a new class of agents, the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.
| Type: | Article |
|---|---|
| Title: | Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.kint.2023.05.009 |
| Language: | English |
| Additional information: | This is an open access article under the CC BY-NC-ND license Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Keywords: | agents, anemia, chronic kidney disease, dialysis, erythropoiesis stimulating, erythropoietin, hemoglobin, hepcidin, hyporesponsiveness, hypoxia-inducible factor-prolyl hydroxylase inhibitors, iron, iron deficiency, major adverse cardiovascular events |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10172977 |
Archive Staff Only
 |
View Item |
